Pfizer Inc. (NYSE:PFE) Shares Acquired by Denali Advisors LLC

Denali Advisors LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 12.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,100 shares of the biopharmaceutical company’s stock after purchasing an additional 4,200 shares during the period. Denali Advisors LLC’s holdings in Pfizer were worth $984,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the 4th quarter valued at about $26,000. Gladius Capital Management LP increased its stake in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the last quarter. Sierra Ocean LLC acquired a new stake in Pfizer during the fourth quarter worth approximately $34,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Pfizer during the 3rd quarter worth approximately $35,000. Finally, Joseph Group Capital Management boosted its holdings in shares of Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Price Performance

Pfizer stock opened at $26.40 on Thursday. The stock has a market capitalization of $149.63 billion, a P/E ratio of 18.73, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm’s 50-day moving average is $26.34 and its two-hundred day moving average is $27.36.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. The company’s revenue was up 24.7% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Guggenheim reiterated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.